Equities

Paragon 28 Inc

Paragon 28 Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)10.53
  • Today's Change0.76 / 7.78%
  • Shares traded552.71k
  • 1 Year change-43.27%
  • Beta--
Data delayed at least 15 minutes, as of May 04 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.

  • Revenue in USD (TTM)216.39m
  • Net income in USD-47.84m
  • Incorporated2021
  • Employees430.00
  • Location
    Paragon 28 Inc14445 Grasslands DriveENGLEWOOD 80112United StatesUSA
  • Phone+1 (720) 912-1332
  • Fax+1 (302) 655-5049
  • Websitehttps://paragon28.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Varex Imaging Corp877.80m44.60m632.95m2.30k23.231.118.010.72110.67120.671216.6514.010.72451.955.90365,750.003.720.99134.321.1832.3731.705.141.362.372.850.4322--3.962.9359.0818.880.2924--
Fulgent Genetics Inc289.21m-167.83m642.86m1.18k--0.5612--2.22-5.64-5.649.7138.310.2207--5.57244,267.70-13.3716.70-14.2518.3736.1267.89-60.5929.06----0.00480.00-53.2768.41-217.03--57.08--
Treace Medical Concepts Inc187.12m-49.53m681.30m516.00--4.92--3.64-0.8154-0.81543.082.230.91071.455.56362,631.80-24.10---29.51--81.20---26.47--3.76--0.2776--31.92---15.68------
Atrion Corp169.33m19.41m730.29m712.0037.653.0121.164.3111.0211.0296.13138.010.64441.447.21237,817.407.3911.967.8512.6236.8441.9911.4619.052.5792.920.0042.42-7.732.12-44.55-10.744.9811.27
Orthopediatrics Corp148.73m-20.97m780.90m247.00--2.04--5.25-0.9251-0.92516.5616.130.34330.40735.01602,153.90-4.84-5.40-5.28-5.9374.8075.09-14.10-15.922.90--0.026--21.6220.91-1,767.25--28.29--
Silk Road Medical Inc185.49m-53.42m799.88m474.00--5.43--4.31-1.37-1.374.763.730.72472.087.87391,322.80-20.87-29.02-22.75-32.9873.3172.91-28.80-46.849.62--0.34--27.7738.66-1.33---7.92--
Cytek Biosciences Inc193.01m-12.15m816.46m676.00--2.07--4.23-0.0887-0.08871.433.010.38071.533.68285,523.70-2.40---2.67--56.69---6.29--5.89--0.0056--17.67---571.58------
BioLife Solutions Inc143.27m-66.43m816.76m409.00--2.41--5.70-1.52-1.523.287.480.3322.465.45350,298.30-15.40-13.76-17.12-15.0432.6336.76-46.36-42.991.83-30.520.0733---11.4348.6552.49--86.35--
Artivion Inc354.00m-30.57m872.99m1.50k--3.05--2.47-0.7496-0.74968.686.860.45531.605.30236,002.70-3.95-2.20-4.24-2.3664.7465.51-8.67-5.343.430.68090.5246--12.826.14-60.09--5.13--
Paragon 28 Inc216.39m-47.84m873.00m430.00--4.91--4.03-0.5819-0.58192.642.150.72760.54845.77503,230.20-16.09---20.14--79.85---22.11--2.30-7.220.3832--19.30--28.94------
Avanos Medical Inc673.30m-9.90m909.30m3.77k--0.73525.121.35-0.2092-1.3214.4326.770.3871.664.73178,546.80-0.5691-0.6527-0.6473-0.733856.3954.45-1.47-1.601.384.270.1196---1.580.6357-146.05---18.37--
AtriCure Inc414.60m-37.23m1.01bn1.20k--2.21--2.44-0.8005-0.80058.929.430.70591.708.21345,501.70-6.34-3.72-7.08-4.1075.2674.36-8.98-7.642.83-13.410.1194--20.8414.6434.49--46.56--
Perspective Therapeutics Inc8.17m-25.10m1.06bn88.00--5.14--130.07-0.1012-0.10120.03510.3520.09444.915.5592,852.27-29.01---31.19--22.96---307.18--2.55--0.0173--------------
MiMedx Group Inc321.48m55.80m1.09bn895.0028.567.5516.973.380.25810.21922.190.9761.573.196.63359,192.2032.86-4.1442.03-5.9083.0183.6120.98-2.703.117.110.256--20.03-2.19310.29---26.47--
Coretag Inc0.00-39.35k1.13bn-----------0.4372-0.43720.00-0.930.00-------78,700.00--------------------------10.95------
Data as of May 04 2024. Currency figures normalised to Paragon 28 Inc's reporting currency: US Dollar USD

Institutional shareholders

23.02%Per cent of shares held by top holders
HolderShares% Held
First Light Asset Management LLCas of 31 Dec 20233.82m4.61%
Braidwell LPas of 31 Dec 20233.36m4.06%
BlackRock Fund Advisorsas of 31 Dec 20233.16m3.82%
The Vanguard Group, Inc.as of 31 Dec 20231.94m2.34%
Bleichroeder LPas of 31 Dec 20231.76m2.13%
Point72 Asset Management LPas of 31 Dec 20231.29m1.55%
SSgA Funds Management, Inc.as of 31 Dec 20231.11m1.34%
Janus Henderson Investors US LLCas of 31 Dec 2023914.25k1.10%
Geode Capital Management LLCas of 31 Dec 2023865.73k1.05%
SEB Investment Management ABas of 31 Dec 2023839.69k1.01%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.